IP Library › Granted Patent US 7,456,257
Granted Patent B2
US 7,456,257 · App. 10/546,112 · Granted Nov 25, 2008

Fusion proteins of interferon alpha muteins with improved properties

Assignee: Merck Patent GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,257
App. No.
10/546,112
Granted
Nov 25, 2008
Kind
B2
Abstract

The invention concerns human interferon alpha and in particular modified forms of interferon alpha 2 with improved properties. The improved proteins contain amino acid substitutions at specific positions that confer increased relative activity in biological assays. The invention provides also modified interferon alpha with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.

Claims (1)

1. A modified IFNα2 molecule represented by SEQ ID NO: 2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2007
From: JONES, TIM; BAKER, MATTHEW; HANLON, MARIAN; CARR, FRANCIS JOSEPH
To: MERCK PATENT GMBH
Reel/Frame 020008/0878 →
Priority Claims (1)
EP 03003647 · Feb 18, 2003 · regional
Continuity (1)
Related Publication 20070148739A1 · Jun 28, 2007